Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Common cardiovascular toxicities in patients with hematological malignancies

Daniel Addison • 15 Dec 2023
ASH 2023
General Checkpoint inhibitors

In this video, Daniel Addison, MD, The Ohio State University Wexner Medical Center, Columbus, OH, outlines some of the most commonly seen cardiovascular (CV) toxicities in his patients and comments on the need to investigate the long-term effects of novel therapies for hematological malignancies on the CV system. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Daniel Addison

0:55
Taking into account CV events as patients with hematological malignancies are treated long-term
Daniel Addison • 15 Dec 2023
1:46
The impact of novel therapies on cardiovascular treatment-related adverse events
Daniel Addison • 15 Dec 2023
6:35
Investigating the cardiovascular toxicities associated with bispecific T-cell engagers
Daniel Addison • 15 Dec 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals